SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-057967
Filing Date
2022-05-10
Accepted
2022-05-10 08:15:43
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2214931d1_8k.htm   iXBRL 8-K 27122
2 EXHIBIT 99.1 tm2214931d1_ex99-1.htm EX-99.1 53224
6 GRAPHIC tm2214931d1_ex99-1img001.jpg GRAPHIC 13006
  Complete submission text file 0001104659-22-057967.txt   282801

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ruby-20220510.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ruby-20220510_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ruby-20220510_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2214931d1_8k_htm.xml XML 3607
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38586 | Film No.: 22907486
SIC: 2836 Biological Products, (No Diagnostic Substances)